Gujarat Themis Biosyn Limited (NSE:GUJTHEM)
India
· Delayed Price · Currency is INR 349.55
+15.80 (4.73%)
At close: Jun 16, 2025, 3:30 PM IST
Gujarat Themis Biosyn Revenue
In the fiscal year ending March 31, 2025, Gujarat Themis Biosyn had annual revenue of 1.51B INR, down -11.20%. Gujarat Themis Biosyn had revenue of 377.36M in the quarter ending March 31, 2025, a decrease of -9.55%.
Revenue
1.51B
Revenue Growth
-11.20%
P/S Ratio
25.26
Revenue / Employee
9.48M
Employees
159
Market Cap
38.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.51B | -190.22M | -11.20% |
| Mar 31, 2024 | 1.70B | 214.37M | 14.45% |
| Mar 31, 2023 | 1.48B | 335.31M | 29.19% |
| Mar 31, 2022 | 1.15B | 242.91M | 26.82% |
| Mar 31, 2021 | 905.63M | 54.38M | 6.39% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 271.45B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Mankind Pharma | 122.07B |
| Aurobindo Pharma | 317.24B |
| Alkem Laboratories | 129.65B |